These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7083242)

  • 41. Induction therapy and intensive consolidation with daunorubicin, cytosine arabinoside, and 6-thioguanine in adult acute nonlymphoblastic leukemia.
    Cassileth PA; Kahn SB; Silber R; Weiler C
    Cancer Clin Trials; 1981; 4(2):125-8. PubMed ID: 7249250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
    Karbasian-Esfahani M; Wiernik PH; Novik Y; Paietta E; Dutcher JP
    Cancer; 2004 Sep; 101(6):1414-9. PubMed ID: 15368329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
    Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
    Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
    Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [High-dose cytosine arabinoside therapy in refractory acute leukemia].
    Yorimitsu S; Takahashi I; Kitazima K; Kimura I; Hara M; Tokuda M
    Rinsho Ketsueki; 1984 Dec; 25(12):1941-6. PubMed ID: 6533329
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacological and biochemical effects of pyrazofurin in humans.
    Ohnuma T; Roboz J; Shapiro ML; Holland JF
    Cancer Res; 1977 Jul; 37(7 Pt 1):2043-9. PubMed ID: 861933
    [No Abstract]   [Full Text] [Related]  

  • 53. High remission induction (traditional sino-western HOAP) regimen for acute nonlymphocytic leukemia.
    Chin Med J (Engl); 1980 Aug; 93(8):565-8. PubMed ID: 6772409
    [No Abstract]   [Full Text] [Related]  

  • 54. Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.
    Lake-Lewin D; Myers J; Lee BJ; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1403-4. PubMed ID: 476714
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II study of pyrazofurin in advanced colorectal carcinoma.
    Creagan ET; Rubin J; Moertel CG; Schutt AJ; O'connell MJ; Hahn RG; Reitemeir RJ; Frytak S
    Cancer Treat Rep; 1977; 61(3):491-3. PubMed ID: 872147
    [No Abstract]   [Full Text] [Related]  

  • 56. Low-dose cytarabine: persistence of a clonal abnormality during complete remission of acute nonlymphocytic leukemia.
    Tilly H; Bastard C; Bizet M; Piguet H; Castaigne S; Degos L
    N Engl J Med; 1986 Jan; 314(4):246-7. PubMed ID: 3941713
    [No Abstract]   [Full Text] [Related]  

  • 57. Central nervous system toxicity of high-dose systemic cytosine arabinoside.
    Lazarus HM; Herzig RH; Herzig GP; Phillips GL; Roessmann U; Fishman DJ
    Cancer; 1981 Dec; 48(12):2577-82. PubMed ID: 7306918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of acute leukoses at the Internal Clinic of the Dr. Z. Kucic Hospital in Rjeka].
    Premuzić-Lampic M
    Bilt Hematol Transfuz; 1976; 4(1-2):53-4. PubMed ID: 1066126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients.
    Tilly H; Castaigne S; Bordessoule D; Sigaux F; Daniel MT; Monconduit M; Degos L
    Cancer; 1985 Apr; 55(8):1633-6. PubMed ID: 3978558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B.
    Mayer RJ; Schiffer CA; Peterson BA; Budman DR; Silver RT; Rai KR; Cornwell GG; Ellison RR; Maguire M; Berg DT
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):25-31. PubMed ID: 3296206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.